It's Monday AM post-@ASCO #GU21 & clinic starts in a couple of hours! Lots to process - I'll try to tackle optimal 1L tx for #kidneycancer. I'll make a case for cabo/nivo, leaning on the beautiful (& timely) tables below from @lalaniMD, @SoaresAndrey & @brian_rini (1/15) What about IO/IO? We have long f/u w #CM214 data w nivo/ipi, no doubt (@AlbigesL et al in @myESMO Open). And treatment-free interval discussed by McDermott @BIDMChealth is no doubt impt. But we've known data not as impressive for favorable risk (2/15)

Excited to share the results of @SWOG 1500, which we are presenting at @ASCO #GU21 & reporting in @TheLancet today. 1st, THANK YOU to patients & families. 2nd, hats off to a tremendous group of investigators. This was a team effort! Wanted to share how it all began: (1/13) A telling snapshot from my "S1500 folder" on my computer. With mentorship from @PrimoLaraMD I submitted the concept 1st in 2012. Had advice from my mentor @DrChoueiri at the time as I conceived of the study design - interestingly, the proposal was XL184 (cabo) v sunitinib! (2/13)

My take on #CheckMate274: Is adj CPI now SOC for #MIUC? Not yet. Here's the design presented today at @ASCO #GU21 - first, thanks to patients & investigators (#DrDeanBajorin, @MattGalsky) who should be commended for completing an adj trial in #bladdercancer - no small feat! (1/9) First, a trip down memory lane. Here is the data from IMvigor010 - adj atezo v observation. No diff in DFS/OS, period. No difference based on PD-L1 status. Could it be PD-1 v PD-L1? Hard to prove. Could it be obs v pbo control? (2/9)